Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0X7DE
|
||||
Former ID |
DAP000042
|
||||
Drug Name |
Nefazodone
|
||||
Synonyms |
Nefazodona; Nefazodonum; Nefazodona [Spanish]; Nefazodone Hcl; Nefazodonum [Latin]; Nefadar (TN); Nefazodone (INN); Nefazodone [INN:BAN]; Serzone (TN); 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antidepressants
|
||||
Company |
Bristol-Myers Squibb
|
||||
Structure |
Download2D MOL |
||||
Formula |
C25H32ClN5O2
|
||||
InChI |
InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3
|
||||
InChIKey |
VRBKIVRKKCLPHA-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 83366-66-9
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9465, 4634333, 7980102, 8152743, 14858579, 29217604, 29223544, 46508323, 48416316, 49665930, 49666410, 50057418, 50111710, 50788542, 56464118, 57322274, 85209875, 85789114, 89736110, 92309073, 93166947, 96024945, 103188221, 103963508, 104306436, 121362268, 124799827, 124893191, 125358294, 126656776, 126684012, 127339542, 127339543, 127339544, 127339545, 129514880, 131327475, 134337370, 135020756, 137001425, 142052543, 144076337, 152046617, 160964483, 163409603, 164828567, 172862753, 175268308, 175610915, 176484419
|
||||
ChEBI ID |
ChEBI:7494
|
||||
SuperDrug ATC ID |
N06AX06
|
||||
SuperDrug CAS ID |
cas=083366669
|
||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 2C receptor | Target Info | Antagonist | [536175], [536286] | |
PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
References | |||||
Ref 536306 | Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. | ||||
Ref 542264 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7247). | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
Ref 536175 | Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. | ||||
Ref 536286 | Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.